NASDAQ:TALS Talaris Therapeutics (TALS) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$15.24▼$16.2150-Day Range$12.36▼$28.3652-Week Range$0.89▼$27.95Volume90,768 shsAverage Volume386,531 shsMarket Capitalization$656.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsDividendHeadlinesInsider TradesOwnershipTrendsStock AnalysisCompetitorsDividendHeadlinesInsider TradesOwnershipTrends Get Talaris Therapeutics alerts: Email Address Ad Paradigm Press Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.Full details are in this announcement. About Talaris Therapeutics Stock (NASDAQ:TALS)Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.Read More Ad Paradigm Press Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.Full details are in this announcement. TALS Stock News HeadlinesAugust 21, 2024 | finance.yahoo.comTourmaline Bio, Inc. (TRML)April 29, 2024 | finanznachrichten.deCullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.February 25, 2024 | benzinga.comLongitude Venture Partners III, L.P.'s Net WorthNovember 1, 2023 | msn.comTalaris Therapeutics (TALS) Price Target Increased by 562.50% to 135.15October 19, 2023 | msn.comTalaris Therapeutics goes ex-dividend tomorrowOctober 18, 2023 | finanznachrichten.deTalaris Therapeutics, Inc.: Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline BioOctober 17, 2023 | msn.comTalaris shareholders approve merger, 1-for-10 reverse stock splitSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.October 17, 2023 | finance.yahoo.comTalaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline BioOctober 6, 2023 | marketwatch.comShares of Talaris Therapeutics Climb 5.2% on Special Dividend Tied to MergerOctober 6, 2023 | finance.yahoo.comTalaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline BioOctober 4, 2023 | finance.yahoo.comNew York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris TherapeuticsSeptember 12, 2023 | finance.yahoo.comWe're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn RateAugust 15, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOTAugust 14, 2023 | finance.yahoo.comImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance BusinessAugust 8, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURFJuly 28, 2023 | benzinga.comMoore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law FirmSee More Headlines Receive TALS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TALS CUSIPN/A CIK1827506 Webtalaristx.com Phone502-398-9250FaxN/AEmployees84Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.93% Return on Assets-37.37% Debt Debt-to-Equity RatioN/A Current Ratio15.41 Quick Ratio15.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.33 per share Price / Book3.55Miscellaneous Outstanding Shares42,764,000Free Float35,708,000Market Cap$656.43 million OptionableNot Optionable Beta2.18 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMs. Mary Kay Fenton (Age 59)Interim CEO, Pres, CFO & Treasurer Comp: $598.98kDr. Suzanne T. Ildstad M.D. (Age 70)Founder, Member of Scientific Advisory Board, Sr. Scientific Advisor & Director Comp: $318.3kMs. Suzanne TollerudVP of Corp. Devel.Key CompetitorsStemline TherapeuticsNASDAQ:STMLFulcrum TherapeuticsNASDAQ:FULCNautilus BiotechnologyNASDAQ:NAUTCalliditas Therapeutics AB (publ)NASDAQ:CALTBioAtlaNASDAQ:BCABView All Competitors TALS Stock Analysis - Frequently Asked Questions How were Talaris Therapeutics' earnings last quarter? Talaris Therapeutics, Inc. (NASDAQ:TALS) issued its quarterly earnings data on Friday, November, 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.03. When did Talaris Therapeutics IPO? Talaris Therapeutics (TALS) raised $150 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO. This page (NASDAQ:TALS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
